Related Experiment Video
Updated: Mar 24, 2026
07:00
Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
Published on: October 13, 2016
8.8K
[Cognitive impairment in amyotrophic lateral sclerosis]
G N Levitsky1, V M Gilod2, R V Chub3
1Russian Charity ALS Foundation, Moscow; 'Real Health Clinic', Moscow; Medical Preventive Ambulatory #51, Moscow.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|March 16, 2016
Summary
Cognitive changes are common in amyotrophic lateral sclerosis (ALS) patients, affecting over a third and correlating with faster disease progression. However, these changes do not impact emotional state or quality of life.
Area of Science:
- Neurology
- Neuroscience
- Cognitive Science
Context:
- Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
- Cognitive and emotional impairments are increasingly recognized in ALS patients.
- Understanding these changes is crucial for comprehensive patient care.
Purpose:
- To assess the prevalence and nature of cognitive and emotional status in ALS patients.
- To investigate the relationship between cognitive changes and disease progression.
- To determine the impact of cognitive changes on emotional well-being and quality of life.
Summary:
- 35.3% of ALS patients exhibited frontotemporal cognitive changes (CC), with 4.2% having dementia.
- Cognitive changes were associated with older age and more rapid ALS progression.
- No significant influence of cognitive changes on emotional state or quality of life was observed.
Impact:
- Highlights the high prevalence of cognitive impairment in ALS.
- Suggests cognitive status as a potential prognostic factor in ALS progression.
- Informs clinical management by indicating that emotional well-being may be preserved despite cognitive deficits.
Related Concept Videos
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:26Cross-bridge Cycle
124.6K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
124.6K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:30Dementia
672
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
672
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
813
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
813